Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials

5 Sept 2023

Abstract excerpt

BACKGROUND: The phase III MONALEESA trials tested the efficacy and safety of the cyclin-dependent kinase (CDK)4/6 inhibitor ribociclib with different endocrine therapy partners as first- or second-line treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer (ABC). Using the largest pooled biomarker dataset of the CDK4/6 inhibitor ribociclib in ABC to date,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Advanced Breast Cancer Therapies
Share to Cancer-related Molecular Pathways
Share to HER2/EGFR in Cancer Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 37673211
DOI: 10.1016/j.annonc.2023.08.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trialsPMID 37673211Read ↗

Acquired gene alterations in patients treated with ribociclib plus endocrine therapy or endocrine therapy alone using baseline and end-of-treatment circulating tumor DNA samples in the MONALEESA-2, -3, and -7 trials.Semantic proximity Read ↗

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer.Semantic proximity Read ↗

Unique molecular signatures as a hallmark of patients with metastatic breast cancer: Implications for current treatment paradigmsSemantic proximity Read ↗

Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancerSemantic proximity Read ↗

Circulating genomic landscape following cyclin-dependent kinase 4/6 inhibitors exposure in HR + /HER2− metastatic breast cancer: a retrospective multi-institutional Consortium analysisSemantic proximity Read ↗

Molecular profiling of a real-world breast cancer cohort with genetically inferred ancestries reveals actionable tumor biology differences between European ancestry and African ancestry patient populations.Semantic proximity Read ↗

Genomic and Transcriptomic Analyses of Breast Cancer Primaries and Matched Metastases in AURORA, the Breast International Group (BIG) Molecular Screening Initiative.Semantic proximity Read ↗

Genomic, Transcriptomic, and Proteomic Profiling of Metastatic Breast Cancer.Semantic proximity Read ↗

Molecular Profile and Matched Targeted Therapy for Advanced Breast Cancer Patients.Semantic proximity Read ↗

Longitudinal multi-omics study of palbociclib resistance in HR-positive/HER2-negative metastatic breast cancerSemantic proximity Read ↗

Real-World Use of Highly Sensitive Liquid Biopsy Monitoring in Metastatic Breast Cancer Patients Treated with Endocrine Agents after Exposure to Aromatase Inhibitors.Semantic proximity Read ↗

Dynamic Monitoring and Identification of Reliable Biomarkers to Predict Efficacy of Bireociclib and Fulvestrant: An Exploratory ctDNA Analysis of the BRIGHT-2 StudySemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.